State Street’s Eledon Pharmaceuticals ELDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.39M | Buy |
1,621,969
+467,298
| +40% | +$1.7M | ﹤0.01% | 2897 |
|
|
2026
Q1 | $3.56M | Buy |
1,154,671
+380,786
| +49% | +$897K | ﹤0.01% | 3093 |
|
|
2025
Q4 | $1.17M | Buy |
773,885
+118,409
| +18% | +$281K | ﹤0.01% | 3489 |
|
|
2025
Q3 | $1.7M | Buy |
655,476
+50,136
| +8% | +$147K | ﹤0.01% | 3388 |
|
|
2025
Q2 | $1.64M | Buy |
605,340
+392,239
| +184% | +$1.18M | ﹤0.01% | 3365 |
|
|
2025
Q1 | $722K | Buy |
213,101
+26,100
| +14% | +$107K | ﹤0.01% | 3508 |
|
|
2024
Q4 | $770K | Buy |
187,001
+25,509
| +16% | +$101K | ﹤0.01% | 3539 |
|
|
2024
Q3 | $402K | Hold |
161,492
| – | – | ﹤0.01% | 3639 |
|
|
2024
Q2 | $426K | Buy |
161,492
+116,800
| +261% | +$279K | ﹤0.01% | 3592 |
|
|
2024
Q1 | $92.1K | Hold |
44,692
| – | – | ﹤0.01% | 4044 |
|
|
2023
Q4 | $80.4K | Hold |
44,692
| – | – | ﹤0.01% | 4098 |
|
|
2023
Q3 | $61.2K | Hold |
44,692
| – | – | ﹤0.01% | 4235 |
|
|
2023
Q2 | $61.2K | Hold |
44,692
| – | – | ﹤0.01% | 4370 |
|
|
2023
Q1 | $105K | Hold |
44,692
| – | – | ﹤0.01% | 4308 |
|
|
2022
Q4 | $104K | Hold |
44,692
| – | – | ﹤0.01% | 4359 |
|
|
2022
Q3 | $123K | Hold |
44,692
| – | – | ﹤0.01% | 4383 |
|
|
2022
Q2 | $109K | Hold |
44,692
| – | – | ﹤0.01% | 4491 |
|
|
2022
Q1 | $176K | Buy |
44,692
+4,257
| +11% | +$16.5K | ﹤0.01% | 4429 |
|
|
2021
Q4 | $178K | Hold |
40,435
| – | – | ﹤0.01% | 4396 |
|
|
2021
Q3 | $250K | Buy |
40,435
+7,500
| +23% | +$52.4K | ﹤0.01% | 4276 |
|
|
2021
Q2 | $261K | Buy |
+32,935
| New | +$311K | ﹤0.01% | 4116 |
|
|
2017
Q2 | – | Sell |
-846
| Closed | -$115K | – | 3711 |
|
|
2017
Q1 | $115K | Sell |
846
-8
| -0.9% | -$1.18K | ﹤0.01% | 3535 |
|
|
2016
Q4 | $136K | Buy |
854
+358
| +72% | +$68.6K | ﹤0.01% | 3518 |
|
|
2016
Q3 | $122K | Buy |
496
+5
| +1% | +$1.83K | ﹤0.01% | 3436 |
|
|
2016
Q2 | $439K | Sell |
491
-45
| -8% | -$49.6K | ﹤0.01% | 3406 |
|
|
2016
Q1 | $487K | Buy |
536
+37
| +7% | +$36.3K | ﹤0.01% | 3356 |
|
|
2015
Q4 | $706K | Buy |
499
+58
| +13% | +$101K | ﹤0.01% | 3284 |
|
|
2015
Q3 | $739K | Buy |
441
+93
| +27% | +$192K | ﹤0.01% | 3267 |
|
|
2015
Q2 | $751K | Buy |
348
+68
| +24% | +$132K | ﹤0.01% | 3303 |
|
|
2015
Q1 | $512K | Buy |
280
+105
| +60% | +$232K | ﹤0.01% | 3365 |
|
|
2014
Q4 | $417K | Buy |
+175
| New | +$415K | ﹤0.01% | 3419 |
|
Other funds holding ELDN
BI
DCM
CCM
ZP
SFM
State Street's ELDN Position: Q2 2026 in Review
State Street increased its Eledon Pharmaceuticals (ELDN) stake by 40% in Q2 2026, buying an estimated $1.7M and bringing the position to 1,621,969 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2897.
State Street first reported a position in ELDN in Q4 2014 and has held it in 31 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.
- State Street held 1,621,969 shares of Eledon Pharmaceuticals worth $6.39M as of Q2 2026.
- State Street bought 467,298 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.7M.
- Eledon Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2897 holding.
- State Street first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 31 quarters since.
- 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.